2. Academic Validation
  3. SENP3 Promotes Hepatocyte Steatosis via De-SUMOylation of SREBP2

SENP3 Promotes Hepatocyte Steatosis via De-SUMOylation of SREBP2

  • Cell Biochem Funct. 2025 Nov;43(11):e70141. doi: 10.1002/cbf.70141.
Qianyu Tang 1 2,  Wenjing Peng 3,  Xiaohua Jiang 3,  Yang Hu 3,  Linxi Chen 1 2,  Nian Fu 3
Affiliations

Affiliations

  • 1 Department of Gastroenterology, School of Basic Medical Sciences, the Affiliated Nanhua Hospital, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, China.
  • 2 Hunan Provincial Key Laboratory for Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China, Hengyang, China.
  • 3 Department of Gastroenterology, The Affiliated Nanhua Hospital, Hengyang Medical School, Clinical Research Center for Metabolic Associated Fatty Liver Disease in Hunan Province, University of South China, Hengyang, Hunan, China.
PMID: 41254938 DOI: 10.1002/cbf.70141
Abstract

SENP3, a member of the sentrin-specific protease family, plays a pivotal role in lipid metabolism and the pathogenesis of fatty liver disease by regulating the dynamic process of SUMOylation. It has previously been demonstrated that SREBP2 is SUMOylated. However, the function and regulatory mechanism of SENP3-mediated SREBP2 de-SUMOylation in hepatocyte steatosis is unclear. Bioinformatic analysis (proteomes from whole cell extract and nuclear extraction, integrated transcriptomes, RNA sequence) SENP3-driven SREBP2 de-SUMOylation in lipid metabolism; Oil red O, nuclear and cytoplasmic extraction, western blot and immunofluorescence suggest SENP3 vitally contributes to hepatocyte steatosis; NLS predictions, CO-IP, co-transfection of plasmids, confocal microscopy indicates nuclear SENP3 associates with SREBP2 to promote its nuclear translocation; molecular docking and mutation assay confirmed SENP3 is responsible for de-SUMOylation SREBP2 at R576. Treatment with OA increased the level of both SENP3 and its nuclear fraction in HepG2 cells. Interfering with the SUMOylation and deSUMOylation cycle induced hepatocyte steatosis by overexpressing SENP3 and using a SUMO inhibitor, GA. Mechanistically, it is observed that the co-localization between SREBP2 and SENP3 is increased. SENP3 is responsible for de-SUMOylation SREBP2 at R576. Moreover, SENP3-mediated de-SUMOylation may also decrease ZMIZ1-ligated SUMO3 binding to SREBP2 at K464 in the nucleus. RNA interference of SREBP2 cannot reverse SENP3-overexpressed cell steatosis under fatty acid treatment. Expression of SREBP2 in vitro could upregulate the nuclear locations of CCTα binding to DNA without altering the active forms. Our findings demonstrate that de-SUMOylation is an important regulatory mechanism that governs the lipid accumulation of SREBP2 in mammalian cells. Also, the critical role of the de-SUMOylation of SREBP2 by SENP3 to exacerbate steatosis may be a potential therapeutic target for metabolic diseases like MAFLD/MASH.

Keywords

MAFLD/MASH; SENP3; SREBP2; de‐SUMOylation; hepatic steatosis.

Figures
Products